INTRODUCTION
The Executive Committee of the Society of Toxicologic Pathology (STP) appointed an ad hoc working group to review the current use of the Peto model for statistical analyses of rodent carcinogenicity study data and to provide recommendations for pathologists regarding appropriate and consistent classi cation of neoplasms for analysis by the Peto model.
The STP held a town hall meeting on June 25, 2001 at the Society's annual meeting to discuss pathologists' contributions to the statistical analyses of rodent carcinogenicity studies. Over 165 people attended this session. Dr. Joseph Haseman, a biostatistician with the National Institute of Environmental Health Sciences, reviewed the Peto test and the manner in which dates of onset of neoplasms are estimated when calculating tumor incidence. There was considerable discussion regarding the use of the date of the animal's death as a surrogate for the date of onset of Fatal neoplasms that had not been identi ed prior to necropsy, and how this assumption was used in the death rate method for calculating incidences of speci c neoplasms. Dr. Haseman also described the poly-k tests that do not use the death rate method to calculate incidence. The participants in the town hall meeting agreed nearly unanimously that: At the request of the STP Executive Committee, the Peto Analysis Working Group reviewed the FDA draft guidance mentioned previously and prepared comments and suggestions for improving the guidance. The Executive Committee has endorsed this response and the response has been sent to the FDA. This response summarizes the STP position on statistical analyses of rodent carcinogenicity study data and other topics discussed in the draft guidance. The full response sent to the FDA follows. These recommendations supersede earlier draft recommendations offered by the Peto Analysis Working Group. 670 0192-6233/01$3.00 $0.00 The Society of Toxicologic Pathology is a nonpro t organization dedicated to improving the discipline of toxicologic pathology through education and professional interactions. The Society's membership includes over 800 pathologists and toxicologists involved in the nonclinical assessment of toxicity and carcinogenicity of chemicals, pharmaceutical candidates, and medical devices. Many of the study pathologists who interpret rodent carcinogenicity studies are members of the Society of Toxicologic Pathology. On June 25, 2001 approximately 165 members of the Society attended a special session at our annual symposium to discuss current statistical methods of rodent carcinogenicity testing. At this meeting, an overwhelming majority believed that pathologists could not accurately and reliably estimate the time of onset of a neoplasm or the length of time a neoplasm had been present based on the gross and microscopic appearances of the neoplasm. The membership also believed that the date of death for a rodent with a neoplasm that caused death of the animal (a Fatal neoplasm) is a very poor estimate of the date of tumor onset for most Fatal neoplasms. These conclusions are very important to the analysis of rodent carcinogenicity study data, since the Peto death rate method uses the date of death as a surrogate for date of onset for all neoplasms that the pathologist classi es as Fatal. with the draft Guidance that, in the context of determining tumor onset, "the dif culty and subjectivity in the determination of cause of death and lethality of a tumor" renders this information "too inaccurate and unobjective to allow valid analysis." As stated in lines 191-193, "The analyses will become biased if the assumption or information on tumor lethality and cause of death is not valid or accurate." The membership of the Society of Toxicologic Pathology believes strongly that neoplasms should not be classi ed as Fatal or Incidental if the Fatal neoplasms are modeled as instantly or rapidly fatal. The Society of Toxicologic Pathology considered dividing Fatal neoplasms into Rapidly Fatal and Not Rapidly Fatal categories, with the time of death used as a surrogate for the time of onset in the Peto analysis only for Rapidly Fatal neoplasms, however, our members are con dent that this new classication could not be done reliably or accurately. Additionally, an acceptable statistical method for estimating time of onset of Not Rapidly Fatal neoplasms was not readily available (1) .
The Society of Toxicologic Pathology recommends that neoplasms not be classi ed as Fatal or Incidental for purposes of determining/analyzing tumor incidence and/or onset. The FDA should accept the Peto analysis using the prevalence method for all neoplasms that cannot be detected at a small size in the living animal or the polyk analysis. The date of onset of super cial, Mortality-Independent neoplasms of the skin, subcutis, and limbs, and other neoplasms that can be reliably detected when small should be analyzed by the onset rate method using the date of rst observation as the date of onset. Deep visceral neoplasms should not be considered Mortality-Independent, even if palpated in life, since these masses cannot be reliably detected when small and date of onset cannot be estimated accurately.
(Note: Identifying the cause(s) of death in individual animals adds signi cant value to interpretation of carcinogenicity studies. Whenever possible, pathologists should identify 'cause of death' for animals dying or killed before scheduled sacri ce as a means to interpret causes of differential mortality among groups, however, this classication cannot be construed to imply date of onset or rate of progression of lesions and cannot be used to model onset of neoplastic or non-neoplastic lesions unless the study is speci cally designed to monitor onset.) 2. Lines 59-72. Dose selection is thoroughly covered in the International Conference on Harmonization guidance S1C Dose Selection for Carcinogenicity Studies of Pharmaceuticals. These lines offer no guidance and should be deleted. 3. Lines 79-92. This paragraph discusses pros and cons of blind evaluation of microscopic slides, but offers no conclusions or guidance. This paragraph should be deleted. 4. Lines 96-97. The FDA guidance should clearly state that a minimum of 50 animals per sex should be assigned to each treatment group. The current statement that 50-60 animals of each sex should be assigned to each group is unnecessarily vague. 5. Lines 1021 and 1066. "CD mice" should read "CD-1 mice."
6. Lines 1045-1046. A single statistical method should be recommended for routine use. The test for trend is more powerful and seems to be the most appropriate method for routine use. Pairwise comparison tests should be performed only if one or more criteria listed in lines 1038-1043 are ful lled. 7. Lines 1112-1114. The genetic background (strain or stock) is the most important factor determining the incidences of spontaneous neoplasms in rodents. Husbandry and housing conditions are often very similar between laboratories and, if similar, will contribute little variation to historical control data. The source (vendor) of the animal model and speci c husbandry practices such as diet optimization or ad libitum feeding may in uence the appropriateness of historical control data to a greater extent than the laboratory conducting the studies. Furthermore, there may not be suf cient historical control data within a single laboratory to make appropriate assessments. In interpreting carcinogenicity studies, it may be necessary and appropriate to pool historical control data from multiple laboratories. We recommend that the guidance state "It is therefore extremely important that the historical control data chosen be from studies comparable to the current study, generally recent studies using the same strain of rodent."
Thank you for the opportunity to comment.
Sincerely, Robert R. Maronpot, D.V.M. Diplomate ACVP Diplomate ABT President, Society of Toxicologic Pathology
